Biocept, Inc. Enters Clinical Collaboration With Sarah Cannon Research Institute Focused On Screening ER+ Breast Cancer Patients
Published: Jun 03, 2015
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that it has entered into a clinical collaboration with Sarah Cannon Research Institute (SCRI), the research arm of Sarah Cannon, the global cancer enterprise of Hospital Corporation of America. The collaboration seeks to determine the clinical utility of detecting biomarkers present in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in blood samples for estrogen positive (ER+) breast cancer patients using Biocept’s OncoCEE™ technology.
“The goal of our collaboration with Sarah Cannon is to identify biomarkers that can be evaluated through a simple blood draw, without continually performing tissue biopsies on a patient”
“The goal of our collaboration with Sarah Cannon is to identify biomarkers that can be evaluated through a simple blood draw, without continually performing tissue biopsies on a patient,” said Biocept Senior Vice President and Senior Medical Director Veena Singh, MD. “By using a blood sample to screen these patients, we seek to help more patients qualify for new drug therapies that can more effectively target cancer.”
Biocept offers a highly sensitive and quantitative blood-based method for the detection and monitoring of biomarkers, which can lead to physicians making better informed treatment decisions based on genomic information.
“Breast cancer is the most prevalent cancer in women, and more than two-thirds of cases express estrogen receptor (ER). It is encouraging to see targeted therapies for patients with ER+ disease, which include recently approved drugs as well as newer options currently available in clinical trials,” said Erika P. Hamilton, MD, Associate Director, Breast Cancer and Gynecologic Cancer Research Program at SCRI. “Understanding a patient’s ER status at the time of diagnosis or recurrence, and then monitoring throughout the patient’s treatment, is becoming increasingly more important.”
The collaboration is designed to demonstrate the utility of Biocept’s liquid biopsy diagnostics to detect biomarker status in cancer patients, and for the assessment of tumor treatment response over time.
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers OncoCEE-GA™ for gastric cancer, OncoCEE-BR™ for breast cancer and OncoCEE-LU™ for non-small cell lung cancer, and plans to introduce CLIA-validated tests for colorectal, prostate and other solid tumors in the near term.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the world’s leading clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 1,000 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors and strategic investigator sites.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to improvement of outcomes, our impact on diagnostic strategies and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.